BPC-157 is claimed to reduce pain, support tissue repair and speed recovery from tendon, ligament, muscle and gut problems.
What BPC-157 does and why that matters
BPC-157 has been studied in cells and animals for steps involved in tissue repair, including whether tendon cells survive, move into an injured area and form new tissue. That gives researchers a reason to ask whether it might reduce pain or shorten recovery after an injury. It does not show that an injection finds a damaged tendon or ligament, rebuilds it, or restores strength and movement in a person. The published human reports have not measured those outcomes well enough to answer that question. [1,2,3,4]
Function evidence: Cell and animal repair findings; human tissue repair not demonstrated
Why people use it and what they report
BPC-157 is claimed to reduce pain and speed recovery from joint, tendon, muscle and gut problems. FDA's 2026 review documented widespread online claims about injury, inflammation, gut symptoms and wound healing. Widespread claims do not show that a treatment works. Online accounts are self-selected, products may differ, and people may also be resting, training differently or receiving other care. They cannot show how often BPC-157 helps, whether it caused an improvement or whether damaged tissue healed. [5]
What supports this description: Community reports and unverified claims; not controlled evidence
BPC-157 Dosing status
Dose: No established human treatment dose | Frequency: No validated schedule for injury recovery or gastrointestinal disease | Cycle: No established cycling schedule | Route: Human reports used specific investigational routes
Preparation: No FDA-approved preparation instructions.
The cited reports do not validate daily subcutaneous internet protocols, injections near injuries or a generic storage period after mixing. [1,2,3,4]
BPC-157 Effects
Tendon research. Laboratory work reported effects on tendon outgrowth, cell survival and migration. These findings do not demonstrate tendon healing in people. [1]
Human knee-pain report. A retrospective series contacted 16 patients: 12 had received BPC-157 alone and four had received BPC-157 plus TB4. Eleven of the 12 BPC-157-only patients said their knee pain improved. The researchers collected the results by phone, follow-up times varied, and there was no control group. They did not use validated measures of function, quality of life, stiffness or daily activity, and they did not use imaging to show that tissue healed. The report supports the narrower statement that some patients recalled less pain. It does not establish that BPC-157 caused the change or repaired the knee. [2]
Intravenous pilot. A two-person pilot reported no observed adverse effects during its limited assessment. That sample cannot rule out uncommon harms or establish long-term safety. [3]
BPC-157 Side Effects
Human safety remains uncertain. FDA identifies possible immunogenicity and peptide-impurity concerns and insufficient safety information for proposed routes. Reliable side-effect frequencies cannot be calculated from these small reports. [3,4]
Frequently Asked Questions About BPC-157
Does BPC-157 have any human data?
Yes. In a retrospective knee-pain series, 11 of 12 people who received BPC-157 alone said their pain improved. The study had no control group, standardized function testing or imaging, so it cannot show that BPC-157 caused the improvement or healed tissue. A separate intravenous safety pilot involved only two people. Neither study establishes a routine treatment protocol. [2,3]
Does injecting near an injury work better?
The cited evidence does not establish that claim. The knee report used intra-articular injections, which are injections into the joint, not subcutaneous injections nearby. [2]
Is oral BPC-157 established for gut problems?
The evidence cited on this page does not establish an effective oral treatment for IBS, ulcers or other gastrointestinal conditions. Route-specific clinical evidence is needed before making those claims. [1,2,3,4]
Evidence
Preclinical studies and small human reports. Animal and laboratory findings have not established an effective human treatment. A small retrospective knee-pain report found that many participants said their pain improved, but it could not show that BPC-157 caused the change or repaired tissue. [1,2,3,4]
Approval status: No FDA-approved BPC-157 product
References
Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol, 2011. PMID 21030672
Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine, 2021. PMID 34324435
Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine, 2025. PMID 40131143
U.S. Food and Drug Administration Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks FDA, 2026. Source
U.S. Food and Drug Administration Pharmacy Compounding Advisory Committee Briefing Document: BPC-157-Related Bulk Drug Substances FDA, 2026. Source
Storage
Educational evidence summary. Approval applies only to the named product and indication; compounded, investigational, and research-market products are different categories.
◇An FDA-approved label or a patient-specific prescription from a licensed pharmacy
◇The active ingredient, strength, dosage form, concentration, lot, and dispensing instructions
◇Identity or purity tests only support the tests performed; they do not prove sterility, endotoxin safety, dose accuracy, stability, or clinical suitability
◇A “research use only” vial is not a patient medicine
